United States · Biotechnology startup
United States · Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Funding reportedLast round: Post-IPO Equity
What company datasets say Artiva Biotherapeutics raised
Funding, as reported
Reported in all$300Min dollars
Last roundPost-IPO Equity
Investors listed5
SEC Form D$163M sold, 2 filings, last Apr 2021
Founders and team
From the SEC filings it signed: 6 on the team.
- Esther J. van den BoomExecutive Officeri
- Fred AslanExecutive Officer, Directori
- Jason J. LittenExecutive Officeri
- Jennifer J. BushExecutive Officeri
- Peter J. FlynnExecutive Officeri
- Thomas J. FarrellExecutive Officeri
On the board, as filediBong J. KohBrian J. DanielsLaura J. StoppelYong-Jun J. HuhYu-Kyeong J. HwangYvonne J. Yamanaka
On a portfolio page
Investors who name them
Each firm lists Artiva Biotherapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Artiva Biotherapeutics in front of investors. Or tell us what we have wrong.